<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Serotonin re-uptake inhibitor antidepressants see Antidepressants; SSRIs see Antidepressants, serotonin re-uptake inhibitor; Antidepressants: serotonin re-uptake inhibitors; Fluoxetine; Citalopram; Escitalopram; Fluvoxamine; Paroxetine; Sertraline" /><meta name="IX" content="Antidepressants: serotonin re-uptake inhibitors; Fluoxetine; Citalopram; Escitalopram; Fluvoxamine; Paroxetine; Sertraline" /><meta name="IXN" content="Serotonin re-uptake inhibitor antidepressants see Antidepressants; SSRIs see Antidepressants, serotonin re-uptake inhibitor" /><title>4.3.3 Selective serotonin re-uptake inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP2413-selective-serotonin-re-uptake-inhibitors.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP2413-selective-serotonin-re-uptake-inhibitors.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP2413-selective-serotonin-re-uptake-inhibitors.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP2092-central-nervous-system.htm">4 Central nervous system</a> &gt; <a href="PHP2347-antidepressant-drugs.htm">4.3 Antidepressant drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP2410-moclobemide.htm" title="Previous: MOCLOBEMIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP2421-citalopram.htm" title="Next: CITALOPRAM">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>4.3.3 </span>Selective serotonin re-uptake inhibitors</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int238-antidepressants-ssri-related.htm">Antidepressants, SSRI (related)</a>,<a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a>).</p></div></div><p><strong>Citalopram</strong>, <strong>escitalopram</strong>, <strong>fluoxetine</strong>, <strong>fluvoxamine,</strong> <strong>paroxetine</strong>, and <strong>sertraline</strong> selectively inhibit the re-uptake of serotonin (5-hydroxytryptamine, 5-HT); they are termed selective serotonin re-uptake inhibitors (SSRIs). For a general comment on the management of depression and on the comparison between <em>tricyclic and related antidepressants</em> and the <em>SSRIs and related antidepressants</em>, see <a title=" Antidepressant drugs" href="PHP2347-antidepressant-drugs.htm">section 4.3</a>.</p> <div class="cI" id="PHP2414"><h3 class="cT">Depressive illness in children and adolescents</h3><p>The balance of risks and benefits for the treatment of depressive illness in individuals under 18 years is considered unfavourable for the SSRIs citalopram, escitalopram, paroxetine, and sertraline, and for mirtazapine and venlafaxine. Clinical trials have failed to show efficacy and have shown an increase in harmful outcomes. However, it is recognised that specialists may sometimes decide to use these drugs in response to individual clinical need; children and adolescents should be monitored carefully for suicidal behaviour, self-harm or hostility, particularly at the beginning of treatment.</p><p>Only fluoxetine has been shown in clinical trials to be effective for treating depressive illness in children and adolescents. However, it is possible that, in common with the other SSRIs, it is associated with a small risk of self-harm and suicidal thoughts. Overall, the balance of risks and benefits for fluoxetine in the treatment of depressive illness in individuals under 18 years is considered favourable, but children and adolescents must be carefully monitored as above.</p></div> <div id="PHP2415"><h2>Cautions</h2><p>SSRIs should be used with caution in patients with epilepsy (avoid if poorly controlled, discontinue if convulsions develop), cardiac disease, diabetes mellitus, susceptibility to angle-closure glaucoma, a history of mania or bleeding disorders (especially gastro-intestinal bleeding), and if used with other drugs that increase the risk of bleeding. They should also be used with caution in those receiving concurrent electroconvulsive therapy (prolonged seizures reported with fluoxetine). SSRIs may also impair performance of skilled tasks (e.g. driving). <strong>Interactions:</strong> see below and Appendix 1 (antidepressants, SSRI).</p></div> <div id="PHP2416"><h2>Withdrawal</h2><p>The risk of withdrawal reactions is higher with paroxetine (see also Withdrawal, <a title="BNF:target-block: Antidepressant drugs and withdrawal" href="PHP2347-antidepressant-drugs.htm#PHP2350">section 4.3</a>). Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, electric shock sensation in the head, neck, and spine, tinnitus, sleep disturbances, fatigue, influenza-like symptoms, and sweating are the most common features of abrupt withdrawal of an SSRI or marked reduction of the dose; palpitation and visual disturbances can occur less commonly. The dose should be tapered over at least a few weeks to avoid these effects. For some patients, it may be necessary to withdraw treatment over a longer period; consider obtaining specialist advice if symptoms persist.</p></div> <div id="PHP2417"><h2>Interactions</h2><p>An SSRI or related antidepressant should not be started until 2 weeks after stopping an MAOI. Conversely, an MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped (2 weeks in the case of sertraline, at least 5 weeks in the case of fluoxetine). For guidance relating to the reversible monoamine oxidase inhibitor, moclobemide, see above. For other SSRI antidepressant interactions, see Appendix 1 (antidepressants, SSRI).</p></div> <div id="PHP2418"><h2>Contra-indications</h2><p>SSRIs should not be used if the patient enters a manic phase.</p> </div> <div id="PHP2419"><h2>Pregnancy</h2><p>Manufacturers advise that SSRIs should not be used during pregnancy unless the potential benefit outweighs the risk. There is a small increased risk of congenital heart defects when SSRIs are taken during early pregnancy. If SSRIs are used during the third trimester there is a risk of neonatal withdrawal symptoms, and persistent pulmonary hypertension in the newborn has been reported; see also individual monographs.</p></div> <div id="PHP2420"><h2>Side-effects</h2><p>SSRIs are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants (<a title="BNF:target-block: Tricyclic antidepressant side-effects" href="PHP2352-tricyclic-and-related-antidepressant-drugs.htm#PHP2360">section 4.3.1</a>). Side-effects of the SSRIs include gastro-intestinal effects (dose-related and fairly common—include nausea, vomiting, dyspepsia, abdominal pain, diarrhoea, constipation), anorexia with weight loss (increased appetite and weight gain also reported) and hypersensitivity reactions including rash (consider discontinuation—may be sign of impending serious systemic reaction, possibly associated with vasculitis), urticaria, angioedema, anaphylaxis, arthralgia, myalgia and photosensitivity; other side-effects include dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions (see Cautions above), galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania (see Cautions above), movement disorders and dyskinesias, visual disturbances, hyponatraemia (see <a title="target-block: Antidepressants CSM advice hyponatraemia" href="PHP2347-antidepressant-drugs.htm#PHP2348">Hyponatraemia and Antidepressant Therapy</a>), and bleeding disorders including ecchymoses and purpura. Suicidal behaviour has been linked with antidepressants (see <a title="target-block: antidepressants and suicide" href="PHP2347-antidepressant-drugs.htm#PHP2349">Suicidal Behaviour and Antidepressant Therapy</a>). Angle-closure glaucoma may very rarely be precipitated by treatment with SSRIs.</p></div> <p><strong>Overdosage</strong>: for advice on overdosage with SSRIs see <a title="BNF:monograph-family: Antidepressants" href="PHP206-antidepressants.htm">Emergency Treatment of Poisoning</a></p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP2421-citalopram"><a href="PHP2421-citalopram.htm" title="CITALOPRAM">CITALOPRAM</a></li><li id="_PHP2424-escitalopram"><a href="PHP2424-escitalopram.htm" title="ESCITALOPRAM">ESCITALOPRAM</a></li><li id="_PHP2426-fluoxetine"><a href="PHP2426-fluoxetine.htm" title="FLUOXETINE">FLUOXETINE</a></li><li id="_PHP2429-fluvoxamine-maleate"><a href="PHP2429-fluvoxamine-maleate.htm" title="FLUVOXAMINE MALEATE">FLUVOXAMINE MALEATE</a></li><li id="_PHP2432-paroxetine"><a href="PHP2432-paroxetine.htm" title="PAROXETINE">PAROXETINE</a></li><li id="_PHP2435-sertraline"><a href="PHP2435-sertraline.htm" title="SERTRALINE">SERTRALINE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP2410-moclobemide.htm">Previous: MOCLOBEMIDE</a> | <a class="top" href="PHP2413-selective-serotonin-re-uptake-inhibitors.htm#">Top</a> | <a accesskey="]" href="PHP2421-citalopram.htm">Next: CITALOPRAM</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>